Business

The biopharmaceutical company, Gilead Sciences, suffered a significant setback as its key drug, Trodelvy, failed to significantly extend the lives of patients with a specific type of lung cancer in a late-stage trial. This news caused a drop of over 10% in Gilead’s shares on Monday. The company had high hopes for Trodelvy, as it